Yet a trial of Secukinumab in nickel-allergic patients demonstrated little-to-no clinical effect after patch testing [108], suggesting that IL-17 is not a major driver of the classical type IV response to nickel, which of course does not rule out that IL-17 plays an important role in rapid-onset ACD. This evidence concerns the gene IL17A and granular corneal dystrophy type II.